M
MAB OF LTD COMPANY
I-Mab Biopharma Co., Ltd. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of biologics to treat diseases including cancers and autoimmune disorders. I-Mab was founded in 2016 and is headquartered in Shanghai, China.
Country/Area ：Russia
Company Email ：zhu.chen@i-mabbiopharma.com
Industry ：HealthcarePharmaceuticals
Company address ：555 W Haiyang Road New Bund Ctr Fl 55-56, Shanghai, Shanghai, China
Company website ：*****
Company phone ：+86 2160578000
Established ：2016
Company Revenue ：$13,157,000
Number of employees ：378
SIC Code ：87873
NAICS Code ：54541
Company News
I-Mab Announces Participation at Jefferies and Piper Conferences in November
Nov 6, 2023
ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel...
Nov 6, 2023
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023Nov 1, 2023
ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific ant
Nov 1, 2023I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023Oct 16, 2023
ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation a
Oct 16, 2023I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503Oct 10, 2023
- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached - Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039 ROCKVILLE, Md. and SHANGHAI, Oct. 10, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discover
Oct 10, 2023Ray Dalio on Potential US-China War and Rise of ChinaOct 5, 2023
In this article, we discuss Ray Dalio on potential US China war and rise of China. If you want to skip our detailed discussion on the US China war and rise of China, head directly to Top 5 Chinese Stocks Bridgewater Associates is Selling. America’s position as a globally dominant force is under threat. Divisive politics, […]
Oct 5, 2023OperationInfo
INN ：7725762256
KPP ：770501001
OKPO ：11262772
OKFS ：24
OKOGU ：4210011
OKOPF ：12300
OKTMO ：45376000000
OKATO ： 45286560 - Замоскворечье, Центральный, Город Москва столица Российской Федерации город федерального значения
Enterprises Nearby ：ООО "МЕТАЛЛ МАРКЕТ", ООО "Алиса Энтерпрайзис", ПРЕД "ОЛЬСЕН ГМБХ & КО. КГ", ООО "СОЮЗ-ВИКТАН"
Founder
| Name | Inn | Share | Sum |
|---|---|---|---|
| ЙОРДАНОВ ИВАЙЛО РОСЕНОВ | 50% | 5 тыс.руб. | |
| КЛАЙМИ КЕННЕТ ГРЭХЭМ | 770475430707 | 50% | 5 тыс.руб. |
ActivityInfo
Main Okved ：Основной (по коду ОКВЭД ред.2): 47.78.5 - Деятельность коммерческих художественных галерей, торговля розничная произведениями искусства в коммерческих художественных галереях
Main Okved Code ：47.78.5
Additional Okveds ：16.29.14,Производство деревянных рам для картин, фотографий, зеркал или аналогичных предметов и прочих изделий из дерева,18.12,Прочие виды полиграфической деятельности,25.99.24,Производство статуэток, рам для фотографий, картин, зеркал и прочих декоративных изделий из недрагоценных металлов,47.61,Торговля розничная книгами в специализированных магазинах,47.63.1,Торговля розничная музыкальными записями, аудиолентами, компакт-дисками и кассетами в специализированных магазинах,47.63.2,Торговля розничная лентами и дисками без записей в специализированных магазинах,47.78.3,Торговля розничная сувенирами, изделиями народных художественных промыслов,47.78.4,Торговля розничная предметами культового и религиозного назначения, похоронными принадлежностями в специализированных магазинах,47.79.1,Торговля розничная предметами антиквариата,47.9,Торговля розничная вне магазинов, палаток, рынков,47.91.2,Торговля розничная, осуществляемая непосредственно при помощи информационно-коммуникационной сети Интернет,47.91.3,Торговля розничная через Интернет-аукционы,47.91.4,Торговля розничная, осуществляемая непосредственно при помощи телевидения, радио, телефона,56.10,Деятельность ресторанов и услуги по доставке продуктов питания,56.10.1,Деятельность ресторанов и кафе с полным ресторанным обслуживанием, кафетериев, ресторанов быстрого питания и самообслуживания,56.10.3,Деятельность ресторанов и баров по обеспечению питанием в железнодорожных вагонах-ресторанах и на судах,56.30,Подача напитков,58.11.1,Издание книг, брошюр, рекламных буклетов и аналогичных изданий, включая издание словарей и энциклопедий, в том числе для слепых, в печатном виде,58.19,Виды издательской деятельности прочие,68.20,Аренда и управление собственным или арендованным недвижимым имуществом,68.20.2,Аренда и управление собственным или арендованным нежилым недвижимым имуществом,68.3,Операции с недвижимым имуществом за вознаграждение или на договорной основе,73.11,Деятельность рекламных агентств,74.20,Деятельность в области фотографии,74.30,Деятельность по письменному и устному переводу,82.92,Деятельность по упаковыванию товаров,82.99,Деятельность по предоставлению прочих вспомогательных услуг для бизнеса, не включенная в другие группировки,90.0,Деятельность творческая, деятельность в области искусства и организации развлечений,90.01,Деятельность в области исполнительских искусств,90.03,Деятельность в области художественного творчества
Pension Fund Registration
Registration Number ：087105130791
Registration Date ：17.04.2023
PfrInstitution Name ：Отделение Фонда пенсионного и социального страхования Российской Федерации по г. Москве и Московской области
Legal Registration Number ：2237703400273
Legal Registration Date ：18.04.2023
Social Insurance Fund Registration
Registration Number ：770404106477041
Registration Date ：18.07.2012
FssInstitution Name ：Отделение Фонда пенсионного и социального страхования Российской Федерации по г. Москве и Московской области
Legal Registration Number ：2127747158064
Legal Registration Date ：19.07.2012
Income Expenditure
Title ：Сведения о доходах и расходах по данным ФНС от 26.11.2024 по ИНН 7725762256:
| Year | Income | Expenditure |
|---|---|---|
| 2023 | 7 912 000 руб. | 28 010 000 руб. |
Web Summary
Q1: What is the address of IMAB Biopharma Co., Ltd.?
A1: The address of IMAB Biopharma Co., Ltd. is 2440 Research Blvd, Suite 400, Rockville, MD 20850, USA.
Q2: What products or therapies does IMAB Biopharma Co., Ltd. focus on developing?
A2: IMAB Biopharma Co., Ltd. focuses on the development of precision immunooncology agents for the treatment of cancer.
Q3: In which industry is IMAB Biopharma Co., Ltd. primarily operating?
A3: IMAB Biopharma Co., Ltd. is primarily operating in the biotechnology and pharmaceutical industry, specifically in the field of oncology.
Q4: What services does IMAB Biopharma Co., Ltd. provide to its customers or patients?
A4: The provided text does not explicitly mention the specific services provided by IMAB Biopharma Co., Ltd. However, as a biotechnology company, it is likely that they provide various services such as clinical trials, manufacturing, and research support.
Q5: What is the contact information for investors and media inquiries?
A5: The contact information for investors and media inquiries is IR@imabbio.com for Investor Relations and BD@imabbio.com for Business Development.
Q6: Who are some of the key executives or members of the management team at IMAB Biopharma Co., Ltd.?
A6: Some of the key executives or members of the management team at IMAB Biopharma Co., Ltd. include XiYong (Sean) Fu, PhD, MBA as CEO, Joseph Skelton as Chief Financial Officer, Phillip Dennis, MD, PhD as Chief Medical Officer, and Claire Xu, MD, PhD as Vice President, Clinical Development.
Q7: What is the company's commitment to Environmental, Social, and Governance (ESG) principles?
A7: The provided text mentions that IMAB Biopharma Co., Ltd. has a "Commitment to ESG" which suggests that they have a strong focus on environmental sustainability, social responsibility, and governance practices.
Q8: What is the company's approach to innovation and scientific research?
A8: The provided text highlights IMAB Biopharma Co., Ltd.'s commitment to innovation and scientific research, with a focus on developing precision immunooncology agents for the treatment of cancer. They also mention their involvement in various scientific publications and presentations, indicating a strong emphasis on advancing knowledge in this field.
Q9: What is the company's approach to expanding access to its therapies?
A9: The provided text mentions that IMAB Biopharma Co., Ltd. has an "Expanded Access Policy" which suggests that they have a policy in place for making their therapies available to patients who may not be eligible for commercial treatment options.
Q10: What is the company's approach to clinical trials and patient safety?
A10: The provided text mentions that IMAB Biopharma Co., Ltd. has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, indicating a focus on conducting rigorous clinical trials to ensure patient safety and efficacy.
Q11: What is the company's approach to portfolio prioritization?
A11: The provided text mentions that IMAB Biopharma Co., Ltd. has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40patient dose expansion study is also planned, indicating a focus on prioritizing their portfolio based on clinical trial results.
Q12: What is the company's approach to media relations and public outreach?
A12: The provided text mentions that IMAB Biopharma Co., Ltd. will present at the Piper Sandler 36th Annual Healthcare Conference in December 2024, indicating a focus on engaging with the media and public through various channels.
Q13: What is the company's approach to partnerships and collaborations?
A13: The provided text mentions that IMAB Biopharma Co., Ltd. has partnered with ABL Bio for the development of their antiPDL1 x 41BB bispecific antibody, indicating a focus on collaborating with other companies to advance their research and development efforts.
Q14: What is the company's approach to intellectual property protection?
A14: The provided text does not explicitly mention IMAB Biopharma Co., Ltd.'s approach to intellectual property protection. However, as a biotechnology company, they likely have policies in place to protect their intellectual property rights.
Note: Some of these questions and answers may require additional research or external information to provide more detailed responses.
A1: The address of IMAB Biopharma Co., Ltd. is 2440 Research Blvd, Suite 400, Rockville, MD 20850, USA.
Q2: What products or therapies does IMAB Biopharma Co., Ltd. focus on developing?
A2: IMAB Biopharma Co., Ltd. focuses on the development of precision immunooncology agents for the treatment of cancer.
Q3: In which industry is IMAB Biopharma Co., Ltd. primarily operating?
A3: IMAB Biopharma Co., Ltd. is primarily operating in the biotechnology and pharmaceutical industry, specifically in the field of oncology.
Q4: What services does IMAB Biopharma Co., Ltd. provide to its customers or patients?
A4: The provided text does not explicitly mention the specific services provided by IMAB Biopharma Co., Ltd. However, as a biotechnology company, it is likely that they provide various services such as clinical trials, manufacturing, and research support.
Q5: What is the contact information for investors and media inquiries?
A5: The contact information for investors and media inquiries is IR@imabbio.com for Investor Relations and BD@imabbio.com for Business Development.
Q6: Who are some of the key executives or members of the management team at IMAB Biopharma Co., Ltd.?
A6: Some of the key executives or members of the management team at IMAB Biopharma Co., Ltd. include XiYong (Sean) Fu, PhD, MBA as CEO, Joseph Skelton as Chief Financial Officer, Phillip Dennis, MD, PhD as Chief Medical Officer, and Claire Xu, MD, PhD as Vice President, Clinical Development.
Q7: What is the company's commitment to Environmental, Social, and Governance (ESG) principles?
A7: The provided text mentions that IMAB Biopharma Co., Ltd. has a "Commitment to ESG" which suggests that they have a strong focus on environmental sustainability, social responsibility, and governance practices.
Q8: What is the company's approach to innovation and scientific research?
A8: The provided text highlights IMAB Biopharma Co., Ltd.'s commitment to innovation and scientific research, with a focus on developing precision immunooncology agents for the treatment of cancer. They also mention their involvement in various scientific publications and presentations, indicating a strong emphasis on advancing knowledge in this field.
Q9: What is the company's approach to expanding access to its therapies?
A9: The provided text mentions that IMAB Biopharma Co., Ltd. has an "Expanded Access Policy" which suggests that they have a policy in place for making their therapies available to patients who may not be eligible for commercial treatment options.
Q10: What is the company's approach to clinical trials and patient safety?
A10: The provided text mentions that IMAB Biopharma Co., Ltd. has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, indicating a focus on conducting rigorous clinical trials to ensure patient safety and efficacy.
Q11: What is the company's approach to portfolio prioritization?
A11: The provided text mentions that IMAB Biopharma Co., Ltd. has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40patient dose expansion study is also planned, indicating a focus on prioritizing their portfolio based on clinical trial results.
Q12: What is the company's approach to media relations and public outreach?
A12: The provided text mentions that IMAB Biopharma Co., Ltd. will present at the Piper Sandler 36th Annual Healthcare Conference in December 2024, indicating a focus on engaging with the media and public through various channels.
Q13: What is the company's approach to partnerships and collaborations?
A13: The provided text mentions that IMAB Biopharma Co., Ltd. has partnered with ABL Bio for the development of their antiPDL1 x 41BB bispecific antibody, indicating a focus on collaborating with other companies to advance their research and development efforts.
Q14: What is the company's approach to intellectual property protection?
A14: The provided text does not explicitly mention IMAB Biopharma Co., Ltd.'s approach to intellectual property protection. However, as a biotechnology company, they likely have policies in place to protect their intellectual property rights.
Note: Some of these questions and answers may require additional research or external information to provide more detailed responses.
Tax Payment
Title ：Сведения об уплаченных суммах налогов и сборов по данным ФНС от 02.10.2024 по ИНН 7725762256:
| Year | TaxName | Sum |
|---|---|---|
| 2023 | Страховые взносы на обязательное медицинское страхование работающего населения, зачисляемые в бюджет Федерального фонда обязательного медицинского страхования | 0 руб. |
| 2023 | Страховые и другие взносы на обязательное пенсионное страхование, зачисляемые в Пенсионный фонд Российской Федерации | 497 933 руб. |
| 2023 | Страховые взносы на обязательное социальное страхование на случай временной нетрудоспособности и в связи с материнством | 0 руб. |
| 2023 | Налог, взимаемый в связи с применением упрощенной системы налогообложения | 0 руб. |
| 2023 | Торговый сбор | 139 974 руб. |
| 2023 | НЕНАЛОГОВЫЕ ДОХОДЫ, администрируемые налоговыми органами | 100 руб. |
| 2023 | Суммы пеней | 46 руб. |
Financial Report
Title ：Результаты работы за 2023 год (по данным ФНС России):
| Code | Indicator | Meaning | Unit |
|---|---|---|---|
| Ф1.1110 | Нематериальные активы | 0 | тыс.руб. |
| Ф1.1120 | Результаты исследований и разработок | 0 | тыс.руб. |
| Ф1.1130 | Нематериальные поисковые активы | 0 | тыс.руб. |
| Ф1.1140 | Материальные поисковые активы | 0 | тыс.руб. |
| Ф1.1150 | Основные средства | 14 | тыс.руб. |
| Ф1.1160 | Доходные вложения в материальные ценности | 0 | тыс.руб. |
| Ф1.1170 | Финансовые вложения | 0 | тыс.руб. |
| Ф1.1180 | Отложенные налоговые активы | 0 | тыс.руб. |
| Ф1.1190 | Прочие внеоборотные активы | 0 | тыс.руб. |
| Ф1.1100 | Итого по разделу I - Внеоборотные активы | 0 | тыс.руб. |
| Ф1.1210 | Запасы | 1298 | тыс.руб. |
| Ф1.1220 | Налог на добавленную стоимость по приобретенным ценностям | 0 | тыс.руб. |
| Ф1.1230 | Дебиторская задолженность | 4864 | тыс.руб. |
| Ф1.1240 | Финансовые вложения (за исключением денежных эквивалентов) | 0 | тыс.руб. |
| Ф1.1250 | Денежные средства и денежные эквиваленты | 216 | тыс.руб. |
| Ф1.1260 | Прочие оборотные активы | 0 | тыс.руб. |
| Ф1.1200 | Итого по разделу II - Оборотные активы | 0 | тыс.руб. |
| Ф1.1600 | БАЛАНС (актив) | 6392 | тыс.руб. |
| Ф1.1310 | Уставный капитал (складочный капитал, уставный фонд, вклады товарищей) | 0 | тыс.руб. |
| Ф1.1320 | Собственные акции, выкупленные у акционеров | 0 | тыс.руб. |
| Ф1.1340 | Переоценка внеоборотных активов | 0 | тыс.руб. |
| Ф1.1350 | Добавочный капитал (без переоценки) | 0 | тыс.руб. |
| Ф1.1360 | Резервный капитал | 0 | тыс.руб. |
| Ф1.1370 | Нераспределенная прибыль (непокрытый убыток) | 0 | тыс.руб. |
| Ф1.1300 | Итого по разделу III - Капитал и резервы | -84920 | тыс.руб. |
| Ф1.1410 | Заемные средства | 90298 | тыс.руб. |
| Ф1.1420 | Отложенные налоговые обязательства | 0 | тыс.руб. |
| Ф1.1430 | Оценочные обязательства | 0 | тыс.руб. |
| Ф1.1450 | Прочие обязательства | 0 | тыс.руб. |
| Ф1.1400 | Итого по разделу IV - Долгосрочные обязательства | 0 | тыс.руб. |
| Ф1.1510 | Заемные средства | 0 | тыс.руб. |
| Ф1.1520 | Кредиторская задолженность | 1014 | тыс.руб. |
| Ф1.1530 | Доходы будущих периодов | 0 | тыс.руб. |
| Ф1.1540 | Оценочные обязательства | 0 | тыс.руб. |
| Ф1.1550 | Прочие обязательства | 0 | тыс.руб. |
| Ф1.1500 | Итого по разделу V - Краткосрочные обязательства | 0 | тыс.руб. |
| Ф1.1700 | БАЛАНС (пассив) | 6392 | тыс.руб. |
| Ф2.2110 | Выручка | 4064 | тыс.руб. |
| Ф2.2120 | Себестоимость продаж | 11591 | тыс.руб. |
| Ф2.2100 | Валовая прибыль (убыток) | 0 | тыс.руб. |
| Ф2.2210 | Коммерческие расходы | 0 | тыс.руб. |
| Ф2.2220 | Управленческие расходы | 0 | тыс.руб. |
| Ф2.2200 | Прибыль (убыток) от продаж | 0 | тыс.руб. |
| Ф2.2310 | Доходы от участия в других организациях | 0 | тыс.руб. |
| Ф2.2320 | Проценты к получению | 0 | тыс.руб. |
| Ф2.2330 | Проценты к уплате | 0 | тыс.руб. |
| Ф2.2340 | Прочие доходы | 3848 | тыс.руб. |
| Ф2.2350 | Прочие расходы | 16419 | тыс.руб. |
| Ф2.2300 | Прибыль (убыток) до налогообложения | 0 | тыс.руб. |
| Ф2.2410 | Текущий налог на прибыль | 30 | тыс.руб. |
| Ф2.2411 | Текущий налог на прибыль | 0 | тыс.руб. |
| Ф2.2412 | Отложенный налог на прибыль | 0 | тыс.руб. |
| Ф2.2421 | В т.ч. постоянные налоговые обязательства (активы) | 0 | тыс.руб. |
| Ф2.2430 | Изменение отложенных налоговых обязательств | 0 | тыс.руб. |
| Ф2.2450 | Изменение отложенных налоговых активов | 0 | тыс.руб. |
| Ф2.2460 | Прочее | 0 | тыс.руб. |
| Ф2.2400 | Чистая прибыль (убыток) | -20128 | тыс.руб. |
| Ф2.2510 | Результат от переоценки внеобор.активов, не включ.в чистую прибыль(убыток) периода | 0 | тыс.руб. |
| Ф2.2520 | Результат от прочих операций, не включаемый в чистую прибыль (убыток) периода | 0 | тыс.руб. |
| Ф2.2530 | Налог на прибыль от операций, результат которых не включается в чистую прибыль | 0 | тыс.руб. |
| Ф2.2500 | Совокупный финансовый результат периода | 0 | тыс.руб. |
| Ф2.2910 | Разводненная прибыль (убыток) на акцию | 0 | тыс.руб. |
| Ф2.2900 | Базовая прибыль (убыток) на акцию | 0 | тыс.руб. |
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
